

# Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/U0507D37578EN.html>

Date: March 2021

Pages: 58

Price: US\$ 125.00 (Single User License)

ID: U0507D37578EN

## Abstracts

Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for patients with long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvida (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX701 for wilson disease; UX053 for glycogen storage disease type III; GTX-102 for the treatment of angelman syndrome in partnership with GeneTx; and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

### Ultragenyx Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Feb 04,2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update

Jan 11,2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories

Jan 08,2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies

Nov 09,2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Ultragenyx Pharmaceutical Inc - Key Facts  
Ultragenyx Pharmaceutical Inc - Key Employees  
Ultragenyx Pharmaceutical Inc - Key Employee Biographies  
Ultragenyx Pharmaceutical Inc - Major Products and Services  
Ultragenyx Pharmaceutical Inc - History  
Ultragenyx Pharmaceutical Inc - Company Statement  
Ultragenyx Pharmaceutical Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Ultragenyx Pharmaceutical Inc - Business Description  
Product Category: Collaboration and License Revenue  
Performance  
Product Category: Crysvida  
Overview  
Performance  
Product Category: Dojolvi  
Overview  
Performance  
Product Category: Mepsevii  
Overview  
Performance  
Product Category: Royalty Revenue  
Performance  
Geographical Segment: All other  
Performance  
Geographical Segment: Europe  
Performance  
Geographical Segment: North America  
Performance  
R&D Overview  
Ultragenyx Pharmaceutical Inc - Corporate Strategy

Ultragenyx Pharmaceutical Inc - SWOT Analysis  
SWOT Analysis - Overview  
Ultragenyx Pharmaceutical Inc - Strengths  
Ultragenyx Pharmaceutical Inc - Weaknesses  
Ultragenyx Pharmaceutical Inc - Opportunities  
Ultragenyx Pharmaceutical Inc - Threats  
Ultragenyx Pharmaceutical Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Ultragenyx Pharmaceutical Inc, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Feb 11, 2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update  
Feb 04, 2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update  
Jan 11, 2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvida in Ultragenyx Territories  
Jan 08, 2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies  
Nov 09, 2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases  
Oct 28, 2020: Ultragenyx announces proposed public offering of common stock  
Oct 27, 2020: Ultragenyx reports third quarter 2020 financial results and corporate

update

Oct 23, 2020: Ultragenyx and Solid Biosciences announce strategic collaboration to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy

Sep 02, 2020: Ultragenyx appoints Mardi C. Dier as Chief Financial Officer

Sep 01, 2020: Ultragenyx expands leadership team and appoints Ernie Meyer as Chief Human Resources Officer

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Ultragenyx Pharmaceutical Inc, Key Facts  
Ultragenyx Pharmaceutical Inc, Key Employees  
Ultragenyx Pharmaceutical Inc, Key Employee Biographies  
Ultragenyx Pharmaceutical Inc, Major Products and Services  
Ultragenyx Pharmaceutical Inc, History  
Ultragenyx Pharmaceutical Inc, Subsidiaries  
Ultragenyx Pharmaceutical Inc, Key Competitors  
Ultragenyx Pharmaceutical Inc, Ratios based on current share price  
Ultragenyx Pharmaceutical Inc, Annual Ratios  
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)  
Ultragenyx Pharmaceutical Inc, Interim Ratios  
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Ultragenyx Pharmaceutical Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

Ultragenyx Pharmaceutical Inc, Performance Chart (2016 - 2020)

Ultragenyx Pharmaceutical Inc, Ratio Charts

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/U0507D37578EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U0507D37578EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970